Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
NCT02109445
Terminated
This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel followed by a Phase 2 portion to evaluate the efficacy of the triple combination in terms of overall survival in patients with metastatic pancreatic ductal adenocarcinoma not previously treated with anticancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2018
Locations: Anschutz Inpatient Pavilion, Aurora, Colorado +4 locations
Conditions: Metastatic Cancer Pancreas
Register for Updates
Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer
NCT03234842
Withdrawn
This study will evaluate if proton beam therapy as part of chemoradiation results in a decrease in diffusion lung capacity of carbon monoxide (DLCO) compared to photon radiation therapy for esophageal carcinoma. A secondary objective is to determine effects on cardiac function, quality of life, and compare acute and late toxicities.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2018
Locations: University of Florida Proton Therapy Institute, Jacksonville, Florida
Conditions: Esophageal Cancer
Register for Updates
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
NCT00876395
Completed
The purpose of this Phase III study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of HER2-overexpressing metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/18/2018
Locations: University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst., Mobile, Alabama +141 locations
Conditions: Breast Cancer
Register for Updates
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00309959
Completed
This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Gender:
FEMALE
Ages:
All
Trial Updated:
12/17/2018
Locations: University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado +25 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
Register for Updates
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00918203
Completed
The purpose of this study is to determine if participants with untreated locally advanced or metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in combination with paclitaxel/carboplatin then when treated with paclitaxel/carboplatin alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2018
Locations: ImClone Investigational Site, Birmingham, Alabama +22 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.
NCT01578551
Terminated
To determine the 1 year progression-free survival (PFS) of the combination of metformin and standard chemotherapy in patients with previously untreated advanced or metastatic pulmonary adenocarcinoma.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/16/2018
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Lung Adenocarcinoma
Register for Updates
Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
NCT02289456
Completed
4 cycles of induction treatment with nab-paclitaxel and carboplatin followed by nab-paclitaxel monotherapy for those subjects who are progression free at the end of 4 cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2018
Locations: University Cancer Institute, Boynton Beach, Florida +7 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
NCT02038647
Completed
This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occurs first) when compared with placebo + paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2018
Locations: Not set, Los Angeles, California +60 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer
NCT00096343
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed. Combining paclitaxel with carboplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin works in treating women who are undergoing surgery for newly diagnosed, locally advanced breast... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
11/30/2018
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama
Conditions: Breast Cancer
Register for Updates
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00287989
Completed
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib together with paclitaxel and carboplatin may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different doses of erlotinib when given together with paclita... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
11/12/2018
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland +1 locations
Conditions: Lung Cancer
Register for Updates
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
NCT00493025
Terminated
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving gefi... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/12/2018
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Esophageal Cancer
Register for Updates
Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
NCT00102622
Terminated
The goal of this clinical research study is to find the highest safe dose of intraperitoneal tgDCC-E1A that can be given in combination with paclitaxel as a treatment for patients with recurrent, platinum-resistant ovarian cancer. How the cancer responds to this treatment will also be studied. Researchers will also ask the patients if they will allow additional tumor samples to be collected and extra blood samples to be drawn. These samples will be used to learn about the biological response bef... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/08/2018
Locations: University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer
Register for Updates